GLYCAN-OPTIMIZED ANTI-CD20 ANTIBODIES
Glycan-optimized monoclonal antibodies that specifically bind CD20 antigen and which have improved effector function are provided. The anti-CD20 antibodies of the invention have a glycosylation pattern that results in an antibody composition having predominately the G0 glycoform, and thus comprise N-glycans that lack fucose (i.e., afucosylated) and galactose residues attached thereto. In some embodiments, these anti-CD20 antibodies comprise the light chain and heavy chain sequences of the rituximab anti-CD20 antibody, and thus represent afucosylated rituximab. Methods for producing these glycan-optimized anti-CD20 antibodies are also provided.
1 . A substantially homogenous anti-CD20 antibody composition, wherein at least 90% of the antibody present in the composition is represented by the G0 glycoform.
2 . The anti-CD20 antibody composition of claim 1 , wherein at least 95% of the antibody present in the composition is represented by the G0 glycoform.
3 . The anti-CD20 antibody composition of claim 1 , wherein about 95% of the antibody present in the composition is represented by the G0 glycoform.
4 . The anti-CD20 antibody composition of claim 1 , wherein said composition comprises a trace amount of precursor glycoform.
5 . The anti-CD20 antibody composition of claim 1 , wherein said antibody exhibits increased binding affinity for an FcγRIII, increased antibody-dependent cellular cytotoxicity (ADCC) activity, decreased complement-dependent cytotoxicity (CDC) activity, or any combination thereof.
6 . The anti-CD20 antibody composition of claim 1 , wherein said anti-CD20 antibody comprises a light chain and a heavy chain of the rituximab antibody.
7 . A pharmaceutical composition comprising the anti-CD20 antibody composition of claim 1 .
8 . A glycoprotein composition comprising a substantially homogeneous N-glycosylation profile, wherein at least 90% of the N-glycans species present in said profile are GlcNAc2Man3GlcNAc2 (G0), said profile comprising a trace amount of precursor N-glycan species, wherein said precursor N-glycan species is selected from the group consisting of Man3GlcNAc2, GlcNac1Man3GlcNAc2 wherein GlcNac1 is attached to the 1,3 mannose arm (MGn), GlcNac1Man3GlcNAc2 wherein GlcNac1 is attached to the 1,6 mannose arm (GnM), and any combination thereof, wherein said glycoprotein is a monoclonal antibody that binds CD20 antigen.
9 . The glycoprotein composition of claim 8 , wherein said monoclonal antibody exhibits increased binding affinity for an FcγRIII, increased antibody-dependent cellular cytotoxicity (ADCC) activity, decreased complement-dependent cytotoxicity (CDC) activity, or any combination thereof.
10 . The glycoprotein composition of claim 8 , wherein said anti-CD20 antibody comprises a light chain and a heavy chain of the rituximab antibody.
11 . A pharmaceutical composition comprising the glycoprotein composition of claim 8 .
12 . A host cell comprising the glycoprotein composition of claim 1 .
13 . The host cell of claim 12 , wherein said host cell is a plant host cell.
14 . The host cell of claim 13 , wherein said plant is a duckweed.
15 . A method for reducing one or more adverse side effects related to complement activation with administration of a monoclonal antibody that binds CD20 antigen, said method comprising administering said antibody in the form of a substantially homogeneous antibody composition, wherein at least 90% of said antibody present in the composition is represented by the G0 glycoform, said composition comprising a trace amount of said antibody represented by a precursor glycoform, wherein said antibody within said composition has decreased complement-dependent cytotoxicity (CDC) activity.
16 . The method of claim 15 , wherein said monoclonal antibody that binds CD20 comprises a light chain and a heavy chain of the rituximab antibody.
17 . The method of 15, wherein said antibody exhibits increased binding affinity for an FcγRIII, increased antibody-dependent cellular cytotoxicity (ADCC) activity, or both increased binding affinity for an FcγRIII and increased antibody-dependent cellular cytotoxicity (ADCC) activity.
18 . A method for treating a human patient having a cancer or autoimmune and/or inflammatory disease that is refractory to treatment with rituximab (Rituxan®), said method comprising administering to said patient a therapeutically effective amount of a substantially homogenous anti-CD20 antibody composition, wherein at least 90% of the antibody present in the composition is represented by the G0 glycoform.
19 . The method of claim 18 , wherein said composition comprises a substantially homogeneous N-glycosylation profile, wherein at least 90% of the N-glycans species present in said profile are GlcNAc2Man3GlcNAc2 (G0), said profile comprising a trace amount of precursor N-glycan species, wherein said precursor N-glycan species is selected from the group consisting of Man3GlcNAc2, GlcNac1Man3GlcNAc2 wherein GlcNac1 is attached to the 1,3 mannose arm (MGn), GlcNac1Man3GlcNAc2 wherein GlcNac1 is attached to the 1,6 mannose arm (GnM), and any combination thereof.